获得性血栓性血小板减少性紫癜患者的长期肾脏结局
基于俄克拉荷马血栓性血小板减少性紫癜登记的前瞻性队列纳入78例首次发作患者,按KDIGO标准评估AKI、按eGFR<60评估CKD。存活的62例中4例(6%)随访出现CKD,AKI与CKD发生无关(P=0.74),无患者需持续肾脏替代治疗。
要点
- 获得性TTP中AKI常见(58%),但重度AKI和需透析者少见。
- 存活患者随访CKD发生率低(6%),AKI与CKD无关联。
- 无患者需要持续肾脏替代治疗,长期肾脏预后总体较好。
核心结论
- 在无选择或转诊偏倚的群体队列中,获得性TTP患者重度AKI和CKD并不常见。
- AKI与后续CKD发生无关(P=0.74)。
- 无患者需要持续肾脏替代治疗。
研究设计与样本
- 研究为前瞻性队列分析,纳入1995至2015年俄克拉荷马TTP登记中78例首次发作的获得性TTP患者。
- AKI按KDIGO标准于诊断时评估,CKD按CKD-EPI方程eGFR<60 ml/min per 1.73 m2于随访时定义。
主要发现
- AKI与患者人口学或就诊临床特征无关联。
- 8例3期AKI中3例死亡;存活的5例eGFR为77至107 ml/min per 1.73 m2(中位数92),中位随访8.1年。
- 62例有随访血肌酐的存活患者中4例(6%)有CKD,中位随访6.4年。
- AKI与CKD发生无关(P=0.74),无患者需要持续肾脏替代治疗。
关键数值与推荐
- AKI诊断采用KDIGO标准。
- CKD定义为eGFR<60 ml/min per 1.73 m2(CKD-EPI方程)。
- 3期AKI定义为需要透析或符合KDIGO 3期标准(原文未详述具体肌酐或尿量阈值)。
临床怎么用
- 获得性TTP患者应关注AKI,但多数不需透析且长期CKD风险低。
- 发生重度AKI存活者肾功能多可恢复至eGFR 77至107 ml/min per 1.73 m2。
- 无需对所有TTP患者常规长期肾病随访,但需个体化评估。
局限性
- 样本量较小(78例),随访血肌酐者仅62例。
- 单中心登记数据,结果外推需谨慎。
- 未报告AKI与CKD关联的多因素校正分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Severe acute kidney injury (AKI) and chronic kidney disease (CKD) are considered to be uncommon in patients with acquired thrombotic thrombocytopenic purpura. However, a recent case series from a tertiary care hospital indicated that 54 (59%) of 92 patients with thrombotic thrombocytopenic purpura presented with AKI; 14 (15%) required dialysis; and 12 (22%) of the 54 patients had CKD at follow-up. METHODS: In this prospective analysis of 78 patients diagnosed with their first episode of thrombotic thrombocytopenic purpura and enrolled in the Oklahoma Thrombotic Thrombocytopenic Purpura Registry from 1995 to 2015, we assessed AKI at diagnosis using Kidney Disease: Improving Global Outcomes criteria, and CKD at follow-up as defined by estimated glomerular filtration rate <60 ml/min per 1.73 m2 determined by the Chronic Kidney Disease-Epidemiology Collaboration equation. RESULTS: Forty-five (58%) patients had AKI; 8 (10%) had stage 3 AKI, and 3 (4%) required dialysis. AKI was not associated with the patients' demographic or presenting clinical features. Three of the 8 patients with stage 3 AKI died; among the 5 survivors, estimated glomerular filtration rate was 77 to 107 ml/min per 1.73 m2 (median, 92) with median follow-up of 8.1 years. Among all 62 surviving patients who have had follow-up serum creatinine measurements, 4 (6%) had CKD with median follow-up of 6.4 years. AKI was not associated with the occurrence of CKD (P = 0.74). No patients have required continuing renal replacement therapy. DISCUSSION: In this population-based prospective cohort of consecutive patients with thrombotic thrombocytopenic purpura, without selection or referral bias, severe AKI and CKD are uncommon.
引用
- Little DJ, Mathias LM, Page EE, et al. Long-term Kidney Outcomes in Patients With Acquired Thrombotic Thrombocytopenic Purpura. Kidney Int Rep. 2017. PMID: 29270517. doi:10.1016/j.ekir.2017.06.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。